Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI dye tracked in urine: new study aims to see how fast it clears

NCT ID NCT06191731

Knowledge-focused Sponsor: Centre Hospitalier Régional Metz-Thionville Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study looks at how quickly gadolinium, a contrast agent used in some MRIs, leaves the body through urine. Researchers will collect urine samples from 60 adults before and up to 2.5 hours after their MRI. The goal is to better understand the body's elimination of this substance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gadolinium-based contrast agents
What this could lead to
If successful, this could help doctors understand how quickly the body clears gadolinium after an MRI, which may improve safety guidelines.
What could go wrong
This is a small, early observational study with only 60 participants. It measures urine levels, not health outcomes, so it won't directly change treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients: * over 18 years of age * with a prescription for MRI with gadolinium-based contrast agents (Gd-CAs) injection validated by a radiologist * affiliated with a health insurance plan * have signed an informed consent form Exclusion Criteria: * Patients: * with known allergy to gadolinium-based contrast agents (Gd-CAs) * with known severe renal impairment (GFR \< 30 mL/min) * on dialysis * with urinary incontinence * with an ongoing urinary tract infection * under hydric or hydrosodic restriction * unable to urinate independently * Protected persons (under guardianship, curatorship or safeguard of justice) * Pregnant or breast-feeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Magnetic resonance imaging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Magnetic resonance imaging

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHR Metz-Thionville / Hopital Bel Air

    RECRUITING

    Thionville, France

  • CHR Metz-Thionville/Hopital de Mercy

    RECRUITING

    Metz, Grand Est, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.